Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Apr 18, 2019 4:51pm
115 Views
Post# 29646941

RE:RE:RE:RE:RE:RE:RE:RE:General response

RE:RE:RE:RE:RE:RE:RE:RE:General response I just went back 5 years to show that the TSX has not been anything special over that time period or even over the last 12 years.

The stock price should be important to management in terms of raising capital/acquiring drugs etc.

However, the stock price has literally cycled between $7 and $9.40 about 4 times in the last 6 months.

This stock is volatile!

The currently reality is that 222 is either liquidating a position, shorting the stock, working on behalf of a buyer or running a malicious algo.

Options expired today and the fast stochastics gave a first sign of a reversal.

I simply think the share price at the end of the month will look different and be more instructive.

bfw

PS my lowest buy was 30 cents and my ACB is around $2 as most of my position was added on the Trogarzo deal




palinc2000 wrote: congratulations if your adjusted cost base is $0.43 
I dont see the pertinence of your comparison between 2 dates  where you are picking  the date of an time low for TH and compare the TSX closing at that date 
What is your point 

You coul have picked another starting date where the SP was in the teens$12dollr or so) and they drove it down to 43 cents,
But more importantly why did you opt to reply this way to my post......You dont think the SP is a currency that should be maximized 


bfw wrote: April 21 2014. TH = $0.43
April 18 2019 TH = $7.03

April 17 2014 TSX = 14500
April 18 2019 TSX = 16600

So, TH returned over 1600%
TSX returned 14.4%

If you want TSX returns buy an ETF.

Otherwise, expect small caps to be more volatile and offer higher potential rewards.

bfw

palinc2000 wrote: TH may need to raise 100 million dollrs thru a share issue and you are saying that the SP is not a priority,,,,on the same day that the canadian markets have closed at an ALL TIME HIGH

You will be the first one whining about the issue price.......

 




Bullboard Posts